📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
11 articles scientifiques publiés — formation continue solide
Expérience confirmée
30 ans d'exercice en rhumatologie — recul clinique solide
30ans d'exercice (thèse 1996)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Direction : Moshe Yaniv
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
[Testicular carcinoma presenting with right lower abdominal pain and retroperitoneal cystic tumor]
2008ArticleJournal de Radiologie
Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer.
2007ArticleEuropean Journal of Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
Purpose This two-part, first-in-human study was initiated in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 tyrosine kinase inhibitor. Patients and Methods Adult patients were treated with escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day cycles. During expansion at the MTD, patients with FGFR1-amplified squamous cell non–small-cell lung cancer (sqNSCLC; arm 1) or other solid tumors with FGFR genetic alterations (mutations/amplifications/fusions) received BGJ398 daily on a continuous schedule (arm 2), or on a 3-weeks-on/1-week-off schedule (arm 3). Results Data in 132 patients from the escalation and expansion arms are reported (May 15, 2015, cutoff). The MTD, 125 mg daily, was determined on the basis of dose-limiting toxicities in four patients (100 mg, grade 3 aminotransferase elevations [n = 1]; 125 mg, hyperphosphatemia [n = 1]; 150 mg, grade 1 corneal toxicity [n = 1] and grade 3 aminotransferase elevations [n = 1]). Common adverse events in patients treated at the MTD (n = 57) included hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), and stomatitis (45.6%). A similar safety profile was observed using the 3-weeks-on/1-week-off schedule (RP2D). However, adverse event–related dose adjustments/interruptions were less frequent with the 3-weeks-on/1-week-off (50.0%) versus the continuous (73.7%) schedule. Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancer. Conclusion BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.
European journal of cancer (Oxford, England : 1990) · 2007
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Future oncology (London, England) · 2020 · Journal Article
Martin M, Garcia-Saenz JA, Manso L, Llombart A, et al.
British journal of cancer · 2017 · Journal Article
Moynahan ME, Chen D, He W, Sung P, et al.
Breast cancer research and treatment · 2014 · Journal Article
Beck JT, Hortobagyi GN, Campone M, Lebrun F, et al.
Cancer discovery · 2014 · Journal Article
Malchers F, Dietlein F, Schöttle J, Lu X, et al.
European journal of cancer (Oxford, England : 1990) · 2007 · Journal Article
Laramas M, Pasquier D, Filhol O, Ringeisen F, et al.
Bulletin du cancer · 2006 · English Abstract
Bolla M, Artignan X, Fourneret P, Brochon D, et al.
Cancer immunology, immunotherapy : CII · 2011 · Clinical Trial, Phase II
Oudard S, Rixe O, Beuselinck B, Linassier C, et al.
Gynecologic oncology · 2010 · Clinical Trial, Phase II
Pautier P, Joly F, Kerbrat P, Bougnoux P, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017 · Clinical Trial, Phase I
Nogova L, Sequist LV, Perez Garcia JM, Andre F, et al.
Breast cancer research : BCR · 2017 · Clinical Trial, Phase III
Toi M, Shao Z, Hurvitz S, Tseng LM, et al.
BMC cancer · 2020 · Journal Article
Davie A, Carter GC, Rider A, Pike J, et al.
BMC cancer · 2020 · Journal Article
Davie A, Carter GC, Rider A, Pike J, et al.